Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Bayer Submits Prostate Cancer Drug Darolutamide in Japan
March 6, 2019
- Pfizer Japan Logs 2.6% Growth in FY2018, No Job Cut Planned: Chief
March 6, 2019
- Sawai Recalls GI Drug after Doping Substance Found
March 6, 2019
- Fujifilm, Tokyo Medical and Dental Univ. Ink Regenerative Medicine Pact for Meniscal Injury
March 6, 2019
- Osteoporosis Drug Evenity Now Available: Amgen Astellas
March 5, 2019
- ASKA to Relocate Kawasaki Research Center to Shonan iPark; 1st Non-Takeda Pharma Tenant
March 5, 2019
- Teijin Pharma’s Feburic Now Available in China
March 5, 2019
- Sumitomo Dainippon to Bolster Functions in Singapore Subsidiary; Maximizing South East Asian Biz
March 5, 2019
- Pfizer Japan Rolls Out EGFR Inhibitor Vizimpro
March 4, 2019
- Kyowa Kirin Resubmits Istradefylline for US Approval for 1st time in 12 Years, Based on Japanese Data
March 4, 2019
- Nichi-Iko Scoops Up FDA-Approved Manufacturing Plant in US from Danish Pharma
March 4, 2019
- Shionogi Strikes Malaria Pact with Nagasaki University
March 1, 2019
- Kaken Grabs Japan Rights to Arbor’s Head Lice Drug
March 1, 2019
- Taisho to Snap Up More Shares in Vietnam’s DHG, Boost Southeast Asian Biz
March 1, 2019
- More Pharmacies Turning to Medical System Network’s Price Negotiation Service after Distribution Guidelines Introduced
March 1, 2019
- JCR’s Hunter Syndrome Drug Earns Orphan Status in Europe
March 1, 2019
- Mitsubishi Tanabe, Servier Tie Up on Tenelia Promotion in China
March 1, 2019
- EMA Accepts Astellas’ AML Drug Xospata for Review, Approval Could Come This Summer
March 1, 2019
- Takeda, Aflac, 6 Other Firms to Develop Insurance with Healthy Living Rewards in 1st Shonan Initiative
February 28, 2019
- Pfizer Transferring MA/Distribution Rights for 3 Off-Patent Brands to Teikoku Seiyaku
February 28, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…